1. Introduction {#s0005}
===============

Parkinson\'s disease (PD) is a progressive neurodegenerative disorder that imposes a significant burden on individuals, their families and healthcare systems ([@bb0135]). While classic motor symptoms of tremor, rigidity and bradykinesia are responsive to dopamine replacement therapies, other features including postural instability/gait difficulty (PIGD) ([@bb0145]) and cognitive impairment, are typically less responsive ([@bb0015]). The severity of these predominantly non-dopaminergic features vary among people with PD, especially in early stages of the disease ([@bb0005]). These features tend to predominate as PD progresses and markedly reduce quality of life ([@bb0080]).

Studies have shown that cerebral small vessel disease (CSVD), manifesting as white matter hyperintensity (WMH) on magnetic resonance images (MRI), is associated with motor deficits ([@bb0020]) and cognitive impairment ([@bb0060]) in older adults. In addition, there is evidence of subcortical arteriosclerosis as well as microinfarcts pathologies at autopsy in adults with motor impairment, a finding that is independent of age, sex, atherosclerosis and dementia diagnosis, suggesting microvascular pathology involvement in motor deficits ([@bb0045]).

Comorbid CSVD in PD is thought to contribute to symptom severity, given the overlap between their clinical features e.g., motor and cognitive impairment ([@bb0030]). A recent study in \>800 people with PD found that WMH and the number of cardiovascular risk factors are related to motor (especially PIGD) and cognitive impairment ([@bb0105]). Other studies have shown that WMH increases in PIGD dominant PD patients compared to the tremor dominant patients ([@bb0075]), and is related to elevated risk of developing dementia ([@bb0010]).

By the time CSVD is manifest in a patient, however, it may be late to alter the prognosis ([@bb0070]). Therefore, it is imperative to develop novel neuroimaging strategies that identify those at risk of developing CSVD. Recent findings support the theory that increased arterial pulsatility contributes to CSVD ([@bb0090]; [@bb0110]). Mechanistically, increased arterial stiffness results in the transmission of higher pulse energy into the downstream cerebral microcirculation; this leads to elevated microvascular pulsatility and likely causes small vessel damage in tissue ([@bb0115]). Therefore, characterizing brain tissue pulsatility is of interest, yet not well studied in PD perhaps due to the limits of observing small-scale hemodynamic features.

Our group has developed a method to non-invasively quantify pulsatility from blood oxygenation level dependent (BOLD) MRI ([@bb0095]). Resting state BOLD images are traditionally used to investigate grey matter functional connectivity whereas white matter (WM) signal are discarded. BOLD signal in WM is of interest because it provides physiological information that is not related to neurovascular BOLD signals and index small vessel related features since few large arteries reside in WM. We define the temporal physiological fluctuations of the BOLD signal within WM as the BOLD tissue pulsatility (BOLD~TP~) ([@bb0095]). We found that BOLD~TP~ was elevated in people with Alzheimer\'s disease, associating directly with memory impairment and inversely with glucose uptake in the brain ([@bb0100]).

The current study used data from the Parkinson\'s Progression Markers Initiative (PPMI) to test whether BOLD~TP~ can explain between-participant differences in PD symptoms. We hypothesized that BOLD~TP~ would be related to neurological symptoms of PD in addition to vascular risk burden. To further develop the utility of BOLD~TP~, we examined BOLD~TP~ relative to WMH volume, WM fractional anisotropy (WM-FA) from diffusion tensor imaging and striatal binding ratio (SBR) of the dopamine transporter (DATSCAN™).

2. Material and methods {#s0010}
=======================

2.1. Participants {#s0015}
-----------------

Data used in the preparation of this article were obtained from the PPMI database ([www.ppmi-info.org/data](http://www.ppmi-info.org/data){#ir0005}). PPMI study was approved by the institutional review board of all participating sites and written informed consent was obtained from all participants before study enrolment. For up-to-date information, visit [www.ppmi-info.org](http://www.ppmi-info.org){#ir0010}. Patients with idiopathic PD, confirmed by DATSCAN™, and available resting state BOLD images were included in this study. Data were collected between 2011 and 2015 and accessed in June 2017.

2.2. Clinical assessments {#s0020}
-------------------------

Motor performance was assessed using the Movement Disorders Society, unified Parkinson\'s disease rating scale part3 (MDS-UPDRS3). We also calculated PIGD and tremor subscores from MDS-UPDRS using a previously established method ([@bb0145]) as a means of studying motor phenotypes. Cognitive performance was assessed by neuropsychological testing that included a revised Hopkins verbal learning test, Benton judgment of line orientation, semantic fluency, letter number sequencing and symbol digit modalities. Clinical characteristics of interest included body mass index, supine pulse pressure and the following cardiovascular risk factors: hypertension, hypercholesterolemia, hyperglycemia/diabetes mellitus and prior cardiovascular disease. We extracted SBR from the processed DATSCAN™ data and calculated mean striatum SBR (i.e., mean of bilateral caudate and bilateral putamen). Details on PPMI DATSCAN™ may be accessed at <http://www.ppmi-info.org/wp-content/uploads/2017/06/PPMI-TOM-V8_09-March-2017.pdf>. SBR analysis was restricted to individuals who completed BOLD MRI and DATSCAN™ acquisitions on the same visit.

2.3. MRI acquisition {#s0025}
--------------------

MRI were acquired on Siemens 3.0 T scanners (Siemens Healthcare, Malvern, PA, USA) from 8 sites using a standardized protocol included: 1) T1-weighted images: TE = 3 ms, TR = 2300 ms, TI = 900 ms, flip angle = 9° and voxel size = 1×1×1mm^3^; 2) resting state BOLD images: TE = 25 ms, TR = 2400 ms, flip angle = 80°, voxel size =3.25×3.25×3.25mm^3^ and number of volumes = 212; 3) interleaved proton density and T2-weighted images: TE = 11 ms and 101 ms, TR = 3270 ms and voxel size = 0.9×0.9×3mm^3^; and 4) diffusion tensor images: TE = 88 ms, TR = 900 ms, voxel size = 2×2×2mm^3^, number of directions = 64, b = 1000s/mm^2^ and one b0 image.

2.4. MRI processing {#s0030}
-------------------

We performed BOLD image processing using the CONN toolbox ([@bb0170]) (MATLAB2015 and SPM12) and in-house tools based on FSL5 ([@bb0065]). Image processing included: 1) motion correction of BOLD images, 2) bias field correction and tissue segmentation of T1-weighted images, and 3) co-registration of BOLD images to Montreal Neurological Institute (MNI152) template space using T1-weighted images as intermediates. The CONN toolbox provides a composite estimate of scan-to-scan movement that is calculated as the maximum movement across 6 control points placed on the image ([@bb0170]). We then calculated the root mean square of these scan-to-scan movements to index the global head motion for each individual. To mitigate issues regarding excessive head motion cases, individuals with global head motion that exceeded 2 mm were excluded from further analyses ([@bb0140]).

We generated a temporal coefficient of variation image from the BOLD time series (i.e., a temporal standard deviation image divided by temporal mean image, expressed as a percentage). We computed thermal noise from non-brain voxels and subtracted this estimate from the temporal coefficient of variation image to isolate physiological sources ([@bb0095]). BOLD~TP~ was calculated as the average BOLD physiological signal in normal appearing WM from the cerebrum. The segmented WM map was masked by a probability threshold of 0.9 and considered a volume of twenty consecutive 2-mm axial slices (inferior-superior range in MNI152 template space was 8-48 mm; [Fig. 1](#f0005){ref-type="fig"}A).Fig. 1A) Coronal and sagittal views to demonstrate the white matter volume of interest in Montreal Neurological Institute template space (MNI152; 2 mm). B) Representative brain tissue pulsatility maps. BOLD~TP~ is indicated in each case.Fig. 1

We segmented WMH using an in-house semi-automated tool based on T1-weighted, proton density and T2-weighted images ([@bb0130]). Diffusion tensor image processing included: 1) correction for head motion and eddy current, 2) co-registration to MNI152 template space using structural images and 3) computation of FA map. More details can be accessed at <http://www.ppmi-info.org/study-design/research-documents-and-sops>. We calculated mean FA in WM (WM-FA) as a global measure using the previously described WM mask ([Fig. 1](#f0005){ref-type="fig"}A).

2.5. Statistical assessments {#s0035}
----------------------------

We performed statistical assessments in R (R 3.2.2 GUI 1.66) with *p* \< .05 observed as significant. We used two separate factor analyses to encapsulate: 1) a composite cognitive score and 2) a vascular risk burden. The cognitive model included: sum of correct words from the three Hopkins verbal learning acquisition trials, the number of correct items from the Benton test, the number of correct unique animal, vegetable and fruit names from the semantic fluency test, the sum of the scores from the seven trials of the letter number sequencing test and the number of correct responses from symbol digit test. The vascular burden model consisted of: body mass index, supine pulse pressure and the diagnosis of cardiovascular risk factors indicated above. Factor analysis (R library: nFactors) extracted latent factors of cognitive and vascular features in two separate models. Scree tests determined the number of factors to retain. Linear regression model assessed the relationship between BOLD~TP~ as the dependent variable and age, sex, MDS-UPDRS3, composite cognitive score, vascular risk burden, PD duration and global head motion as independent variables. To test the effect of brain volume on BOLD~TP~, we added brain volume to the above-mentioned model secondarily. We also used bivariate correlation to examine whether motor impairment is related to more severe head motion. To investigate different motor phenotypes of PD, we assessed the association of BOLD~TP~ with PIGD and tremor subscores using bivariate correlations.

We performed bivariate correlations between each of the following variables: BOLD~TP~, WMH volume and WM-FA. In a subgroup of individuals that also underwent DATSCAN™ at the same visit as MRI, we performed bivariate correlations between SBR and WM measures (BOLD~TP~, WMH volume, WM-FA). Linear regression examined the relationship of PD neurological symptoms (dependent variable) with BOLD~TP~ and SBR (independent variables).

3. Results {#s0040}
==========

BOLD data were available for 86 people with PD. Five participants were excluded due to excessive global head motion (\>2 mm). Therefore, 81 adults with PD were included in this analysis. Age ranged from 38 to 78 years (mean = 61; SD = 10.6), the sample was predominantly male (56 out of 81 participants) and disease duration ranged from 1 to 50 months (mean = 20; SD = 11.5). Montreal Cognitive Assessment scores (MoCA) ranged from 15 to 30 (mean = 26.7; SD = 2.9). MDS-UPDRS3 ranged from 6 to 51 (mean = 20.3; SD = 10.8), the PIGD subscore ranged from 0 to 1.2 (mean = 0.27; SD = 0.23) and the tremor subscore ranged from 0 to 2.2 (mean = 0.57; SD = 0.46). Approximately 50% of participants had at least one cardiovascular risk factor (42 out of 81). The BOLD~TP~ values ranged from 0.8 to 1.47 (mean = 1.04; SD = 0.13). [Fig. 1](#f0005){ref-type="fig"}B shows representative BOLD~TP~ maps from three individuals. Global head motion estimates ranged from 0.2 to 1.9 mm (mean = 0.81; SD = 0.45). Brain volume ranged from 1809 to 2378 cm^3^ (mean = 2130; SD = 91.5).

The Scree test revealed one factor was sufficient to describe the latent cognitive state. This factor explained 43% of the overall variance ([Table 1](#t0005){ref-type="table"}). One factor was also sufficient for the vascular risk model, which explained 21% of the overall variance ([Table 2](#t0010){ref-type="table"}). The regression model revealed that MDS-UPDRS3 (*t* = 2.3; *p* = .02), vascular risk burden (2.4; p = .02), male sex (*t* = 3.0; *p* = .003) and global head motion (*t* = 3.2, *p* = .001), but not age, cognition and PD duration (*p* \> .7) were associated with BOLD~TP~ (model r^2^ = 0.4, *p* \< .0001). Including brain volume in this model did not change the relationship of BOLD~TP~ with MDS-UPDRS3, vascular risk burden, sex nor head motion, as each of these independent variables remained significant (*p* \< .05), while brain volume parameter estimate was not (*p* \> .1). We did not observe significant correlation between MDS-UPDRS3 and global head motion (*N* = 81; *p* \> .14). Supplementary Fig. 1 shows the scatter plot of global head motion vs. MDS-UPDRS3 for the whole sample. However, we observed a significant correlation between BOLD~TP~ and PIGD (*r* = 0.21, *p* = .05), while there was no correlation between BOLD~TP~ and tremor subscore (*p* = .4), meaning that people with higher postural instability and gait difficulty had elevated BOLD~TP~.Table 1Correlation of composite cognitive score and individual cognitive tests.Table 1Correlation coefficientsHopkins verbal learning test0.72[⁎](#tf0005){ref-type="table-fn"}Benton judgment of line orientation0.28[⁎](#tf0005){ref-type="table-fn"}Semantic fluency0.63[⁎](#tf0005){ref-type="table-fn"}Letter number sequencing0.72[⁎](#tf0005){ref-type="table-fn"}Symbol digit modalities0.97[⁎](#tf0005){ref-type="table-fn"}[^1]Table 2Correlation of vascular risk burden with individual clinical variables.Table 2Correlation coefficientsBody mass index0.69[⁎](#tf0010){ref-type="table-fn"}Pulse pressure0.42[⁎](#tf0010){ref-type="table-fn"}Hypertension0.45[⁎](#tf0010){ref-type="table-fn"}Hypercholesterolemia0.69[⁎](#tf0010){ref-type="table-fn"}Hyperglycemia/Diabetes0.68[⁎](#tf0010){ref-type="table-fn"}Prior cardiovascular disease0.46[⁎](#tf0010){ref-type="table-fn"}[^2]

WMH volumes ranged from 0.016 to 2.12 cm^3^ (mean = 0.32; SD = 0.37). WMH volume was log-transformed to reduce skewness. BOLD~TP~ and WMH volume was significantly correlated (*r* = 0.22, *p* = .05; [Table 3](#t0015){ref-type="table"}). WM-FA ranged from 0.42 to 0.55 (mean = 0.48; SD = 0.02) and was correlated with WMH volume (*r* = −0.35; *p* = .002) but not BOLD~TP~ ([Table 3](#t0015){ref-type="table"}).Table 3Bivariate correlation coefficients among WM metrics and SBR.Table 3WMHWM-FASBR[\#](#tf0020){ref-type="table-fn"}BOLD~TP~0.22[⁎](#tf0015){ref-type="table-fn"}−0.180.07WMH--−0.35[⁎](#tf0015){ref-type="table-fn"}−0.14WM-FA--0.11[^3][^4][^5]

In the subgroup of 52 people with corresponding DATSCAN™, SBR values ranged from 0.17 to 1.95 (mean = 1.2; SD = 0.38). SBR was not correlated with BOLD~TP~, WMH volume or WM-FA ([Table 3](#t0015){ref-type="table"}; *p* \> .3). Linear regression showed that BOLD~TP~ (*t* = 2.76, *p* = .008) and SBR (*t* = −2.04, *p* = .04) independently contributed to between subject differences in MDS-UPDRS3 (model r^2^ = 0.18, *p* = .006). [Fig. 2](#f0010){ref-type="fig"}A and B illustrate MDS-UPDRS3 with respect to BOLD~TP~ and SBR, respectively.Fig. 2Motor performance (MDS-UPDRS3) with respect to A) brain tissue pulsatility (BOLD~TP~) (t = 2.76, p = .008) and B) striatal binding ratio (SBR) (*t* = −2.04, *p* = .04).Fig. 2

4. Discussion {#s0045}
=============

This study demonstrates that brain tissue pulsatility, extracted from dynamic BOLD signal in WM, is related to neurological and vascular features in PD. In support of the primary hypothesis, BOLD~TP~ was directly related to MDS-UPDRS3 and PIGD. Interestingly, BOLD~TP~ was not directly related to SBR, yet both measures independently contributed to motor dysfunction, reinforcing the comorbid influence of CSVD in PD.

BOLD~TP~, independent of SBR, was related to motor performance which is in agreement with a previous study that showed microvascular damage is related to motor dysfunction ([@bb0045]). Microvascular pulsatility contributes to motor dysfunction through the following possible mechanisms: 1) small vessel damage within subcortical substantia nigra and/or striatal regions that may lead to more severe parkinsonism; and 2) disruption of small vessel function involving the WM may disrupt the corticostriatal--thalamocortical loops and interhemispheric connections of corpus callosum which are essential for motor functions ([@bb0030]). In contrast to the association with motor dysfunction, BOLD~TP~ was not related to global cognition. This lack of association may be due to a relatively preserved cognitive function for this group, as reflected by the narrow range of MoCA scores and is consistent with the early stages of PD ([@bb0080]).

BOLD~TP~ was associated with vascular risk burden, in agreement with previous reports of the impact of vascular risk factors on cerebral hemodynamics ([@bb0085]; [@bb0050]). Since vascular risk burden was strongly correlated with vascular health measures, we conclude that BOLD~TP~ was associated with pulse pressure, body mass index and the presence of vascular risk factors e.g., hypertension. These results are in line with studies that show vascular risk factors are associated with higher risk of CSVD ([@bb0155]). Previous researchers showed that increased aortic stiffness and morphological changes to small vessels are associated with CSVD ([@bb0165]; [@bb0120]). Arterial stiffness increases pulsatile energy transmitted into cerebral circulation. The increased vascular rigidity and higher resistance are thought to develop in response to increased pulsatility ([@bb0125]), thus making the surrounding tissue more susceptible to ischemic lesions ([@bb0055]). Deep brain structures such as WM and basal ganglia are more susceptible to this phenomenon since they are perfused by short, penetrating arterioles with minimal damping ability to dampen the high input pressure ([@bb0030]).

Previously, we found that BOLD~TP~ was lower within the WMH compared to normal appearing WM ([@bb0095]) which might relate to reduced vascular density as reported in ([@bb0040]); however, BOLD~TP~, i.e., pulsatility in normal appearing WM, was related to WMH volume suggesting that people with higher burden of CSVD have higher BOLD~TP~ ([@bb0095]) and the direction of this association is consistent with the findings in the current study. Others have also reported on the association between WMH volume and WM-FA ([@bb0070]; [@bb0090]), suggesting the presence of pathological processes involving demyelination and axonal loss in WMH ([@bb0160]). Previous studies showed that WM-FA is associated with arterial pulsatility ([@bb0070]) and aortic stiffness ([@bb0090]). We, however, did not find an association between WM-FA and BOLD~TP~. One possible reason is that BOLD~TP~ represents microvascular pulsatility while these studies measured pulsatility of large vessels. Further research is needed to examine BOLD~TP~ in relation to large vessel pulsatility, such as using transcranial Doppler ultrasound to study intracranial arteries as conduits for pulsatility or other MRI techniques like multi-shell diffusion tensor imaging that attempt to separate bulk water from WM signals ([@bb0025]).

This study has some limitations. First is the absence of a control group; therefore, we are unable to comment on whether BOLD~TP~ is increased in PD relative to healthy controls. To date, there are insufficient PPMI controls (*n* = 17) to warrant such analysis. Second, the BOLD acquisition had a temporal resolution of 2400 ms. Consequently, it is not possible to resolve cardiac from respiratory physiological sources and a proportion of BOLD~TP~ variance may be due to respiratory signals ([@bb0035]). Recording these physiological traces would allow the separation of these sources during post-processing ([@bb0150]), but these data were not available. Third, the vascular risk factor explained only a modest amount of variance for the vascular model, but this factor nonetheless was highly correlated with the model variables and found to increase in direct association with BOLD~TP~, which was in line with our hypothesis.

Finally, in addition to physiological sources, there are other sources of temporal variability in BOLD signal, namely thermal noise and head motion, which we attempted to account for in the BOLD~TP~ analyses. Although BOLD~TP~ was related to global head motion as we observed before ([@bb0100]), we did not find a significant relationship between motor impairment and head motion, suggesting that the relationship of BOLD~TP~ and motor impairment was not contaminated by head motion. We also excluded excessive head motion individuals from the outset of the analysis, which is in line with fMRI convention. As illustrated in Supplementary Fig. 1, however, excessive head motion was not related to motor symptom severity in this cohort.

In summary, this study demonstrated that BOLD based brain tissue pulsatility explains PD symptom heterogeneity, independent of dopaminergic deficits. BOLD~TP~ was not only related to vascular risk burden but also was associated with neurological features of PD, notably motor dysfunction. BOLD~TP~ may be an adjunctive neuroimaging measure that can explain PD symptoms, in particular features that relate to small vessel alterations.
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[^1]: *p* \< .01.

[^2]: *p* \< .01.

[^3]: BOLD~TP~: BOLD tissue pulsatility / WMH: white matter hyperintensity volume / WM-FA: white matter fractional anisotropy / SBR: striatal binding ratio.

[^4]: *p* \< .05.

[^5]: *n* = 52.
